New insider activity at BridgeBio Pharma ( (BBIO) ) has taken place on November 14, 2025.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Director Hannah Valantine has recently sold 25,484 shares of BridgeBio Pharma stock, amounting to a total transaction value of $1,683,727.
Recent Updates on BBIO stock
In the last 24 hours, BridgeBio Pharma has seen several price target increases from major financial institutions, driven by a combination of successful clinical trial results and strong financial performance. Wells Fargo raised its price target due to anticipated upside in Attruby estimates and potential clarity on Tafamidis Gxs, alongside a high probability of success in the Phase 3 readout for infigratinib in early 2026. Goldman Sachs significantly increased its target following BridgeBio’s Q3 results, which showed strong commercial momentum for Attruby, with U.S. sales exceeding estimates and a notable increase in prescriptions. The firm’s transition towards a multi-product, profitable biotech is seen as on track, offering further upside potential. Additionally, BridgeBio presented promising data from the ATTRibute-CM study, which demonstrated significant reductions in all-cause mortality with acoramidis. Despite these positive developments, the company faces challenges related to market access and rising operating expenses, as highlighted in their recent earnings call.
Spark’s Take on BBIO Stock
According to Spark, TipRanks’ AI Analyst, BBIO is a Neutral.
BridgeBio Pharma’s overall stock score is driven by strong earnings call results and technical momentum, offset by financial instability and poor valuation metrics. The company’s growth potential is evident, but significant risks remain due to high leverage and cash flow challenges.
To see Spark’s full report on BBIO stock, click here.
More about BridgeBio Pharma
YTD Price Performance: 130.71%
Average Trading Volume: 2,372,383
Technical Sentiment Signal: Buy
Current Market Cap: $12.76B